Metabolic Health
GLP-1 and Inflammation
Semaglutide measurably lowers a key inflammation marker in trial data, independent of how much weight is lost. Here is w...
Eligibility for weight loss medication is anchored to BMI, and the standard thresholds were derived from Western populations. That creates a specific problem for South Asian patients.
Here is what the standard criteria are, why they may understate risk in Pakistan, and what else matters alongside the number.
The standard thresholds
Across approved weight management medications, eligibility is generally:
BMI 30 or above, classified as obesity, or
BMI 27 or above with at least one weight-related condition, such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnea.
SURMOUNT-1, published in the New England Journal of Medicine, used exactly this structure, enrolling adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition.
What BMI actually measures
BMI is weight in kilograms divided by height in metres squared. It is a screening tool, not a diagnosis.
Standard categories:
| Category | BMI |
|---|---|
| Underweight | Below 18.5 |
| Healthy weight | 18.5 to 24.9 |
| Overweight | 25 to 29.9 |
| Obesity | 30 and above |
Its value is that it is quick, free and correlates reasonably with health risk across populations.
Its limitations are well known. It does not distinguish muscle from fat, so a muscular person can register as overweight without excess fat. It does not indicate where fat is distributed, which matters considerably. And it was derived from European populations, which is the problem relevant here.
The South Asian adjustment
This is the part that changes the answer for readers in Pakistan.
South Asian populations carry proportionally more visceral fat, the metabolically active fat around the organs, and less subcutaneous fat, at any given BMI.
Visceral fat drives insulin resistance, fatty liver and cardiovascular risk directly. So the same BMI represents more metabolic risk in a South Asian body than in a European one.
The consequences are documented. South Asians develop type 2 diabetes at lower BMI and younger ages. Fatty liver occurs at lower body weights. Cardiovascular disease presents earlier.
For this reason, some guidance applies lower BMI cut-offs for South Asian populations, commonly placing overweight around 23 and obesity around 27, rather than 25 and 30.
WHO's obesity fact sheet sets out the health consequences of excess weight generally.
The practical implication is direct. A Pakistani adult at BMI 27 may carry the metabolic risk that a European adult carries at 30.
Waist circumference
Because BMI misses fat distribution, waist measurement adds information cheaply.
It reflects visceral fat directly, which is what BMI cannot see.
Commonly cited thresholds for South Asian populations are lower than the standard ones, generally around 90 cm for men and 80 cm for women, against 102 cm and 88 cm in Western guidance.
Measure at the midpoint between the lowest rib and the top of the hip bone, standing, at the end of a normal breath out. Not pulled in.
Someone with a BMI of 26 and a waist above the threshold carries more risk than the BMI alone indicates.
What else determines eligibility
BMI is the entry criterion, not the whole assessment.
Weight-related conditions lower the threshold and increase the benefit. High blood pressure, type 2 diabetes or prediabetes, dyslipidaemia, obstructive sleep apnea, fatty liver, PCOS and weight-bearing joint disease all count.
Contraindications override eligibility regardless of BMI. A personal or family history of medullary thyroid carcinoma or MEN2, previous pancreatitis, pregnancy and breastfeeding all rule these medications out whatever your weight.
What you have already tried matters. Medication is generally considered alongside rather than instead of dietary and activity change.
Whether your problem is appetite. If eating is driven by emotion rather than hunger, or if you eat sensibly and gain weight anyway, appetite medication may be the wrong tool regardless of BMI.
Where BMI misleads in both directions
It can overstate risk in muscular people, since muscle weighs more than fat. A heavily built person may register as overweight without excess fat.
It can understate risk in people with low muscle mass and high visceral fat, sometimes described as normal weight obesity. Someone at BMI 24 with a large waist and poor muscle mass may carry considerable metabolic risk.
It says nothing about trajectory. Someone at BMI 28 who has gained 10 kg in two years is in a different situation from someone stable at 28 for a decade.
What to do with the number
Calculate your BMI as a starting point, then add context.
Measure your waist. Note any weight-related conditions. Consider your family history of diabetes and cardiovascular disease. Consider whether your weight is stable or rising.
That combination gives a better picture than a single number, and it is what a proper assessment covers.
A locally registered GLP-1 supplement includes physician review before dispatch, which is where BMI, waist, conditions and contraindications get considered together. METASLIM™ is a physician-reviewed sublingual supplement rather than a pharmaceutical GLP-1 receptor agonist, and it is intended for adults rather than for anyone at a healthy weight.
Our guide to who should not take GLP-1 medication covers the contraindications, and weight loss and diabetes prevention covers why the South Asian thresholds matter.
The summary
Standard eligibility is BMI 30 or above, or 27 or above with a weight-related condition, which is the structure SURMOUNT-1 used.
BMI was derived from European populations and understates metabolic risk in South Asian bodies, which carry more visceral fat at any given weight.
Some guidance applies lower South Asian thresholds, around 23 for overweight and 27 for obesity.
Waist circumference reflects visceral fat directly, with South Asian thresholds around 90 cm for men and 80 cm for women.
Contraindications override eligibility regardless of BMI.
BMI can overstate risk in muscular people and understate it in those with low muscle and high visceral fat.
See if you qualify for the program with BMI, waist and conditions assessed together.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.